Upjohn Drug Patent Portfolio
Upjohn owns 9 orange book drugs protected by 63 US patents with Detrol having the least patent protection, holding only 1 patent. And Inspra with maximum patent protection, holding 16 patents. Given below is the list of Upjohn's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10022447 | Solid pharmaceutical compositions containing pregabalin | 02 May, 2027 | Active |
| US8945620 | Solid pharmaceutical compositions containing pregabalin | 02 May, 2027 | Active |
| US9144559 | Solid pharmaceutical compositions containing pregabalin | 02 May, 2027 | Active |
| US10022447 | Solid pharmaceutical compositions containing pregabalin | 02 Nov, 2026 | Active |
| US8945620 | Solid pharmaceutical compositions containing pregabalin | 02 Nov, 2026 | Active |
| US9144559 | Solid pharmaceutical compositions containing pregabalin | 02 Nov, 2026 | Active |
| US6863902 | Immediate release eplerenone compositions | 10 Oct, 2020 | Expired |
| US6410054 | Immediate release eplerenone compositions | 08 Jun, 2020 | Expired |
| US6495165 | Eplerenone compositions having improved bioavailability | 08 Jun, 2020 | Expired |
| US6534093 | Immediate release eplerenone compositions | 08 Jun, 2020 | Expired |
| US6558707 | Immediate release eplerenone compositions | 08 Jun, 2020 | Expired |
| US7157101 | Micronized eplerenone compositions | 08 Jun, 2020 | Expired |
| US6630162 | Pharmaceutical formulation and its use | 11 May, 2020 | Expired |
| US6911217 | Controlled release bead, a method of producing the same and multiple unit formulation comprising it | 11 May, 2020 | Expired |
| US6410524 | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease | 05 May, 2020 | Expired |
| US6747020 | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor | 05 May, 2020 | Expired |
| US6863902 | Immediate release eplerenone compositions | 10 Apr, 2020 | Expired |
| US6770295 | Therapeutic formulation for administering tolterodine with controlled release | 26 Feb, 2020 | Expired |
| US6410054 | Immediate release eplerenone compositions | 08 Dec, 2019 | Expired |
| US6495165 | Eplerenone compositions having improved bioavailability | 08 Dec, 2019 | Expired |
| US6534093 | Immediate release eplerenone compositions | 08 Dec, 2019 | Expired |
| US6558707 | Immediate release eplerenone compositions | 08 Dec, 2019 | Expired |
| US7157101 | Micronized eplerenone compositions | 08 Dec, 2019 | Expired |
| US6630162 | Pharmaceutical formulation and its use | 11 Nov, 2019 | Expired |
| US6911217 | Controlled release bead, a method of producing the same and multiple unit formulation comprising it | 11 Nov, 2019 | Expired |
| US6410524 | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease | 05 Nov, 2019 | Expired |
| US6747020 | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor | 05 Nov, 2019 | Expired |
| US6770295 | Therapeutic formulation for administering tolterodine with controlled release | 26 Aug, 2019 | Expired |
| US6001876 | Isobutylgaba and its derivatives for the treatment of pain | 30 Jun, 2019 | Expired |
| US6197819 | Gamma amino butyric acid analogs and optical isomers | 30 Jun, 2019 | Expired |
| USRE41920 | Isobutylgaba and its derivatives for the treatment of pain | 30 Jun, 2019 | Expired |
| US6001876 | Isobutylgaba and its derivatives for the treatment of pain | 30 Dec, 2018 | Expired |
| US6197819 | Gamma amino butyric acid analogs and optical isomers | 30 Dec, 2018 | Expired |
| USRE41920 | Isobutylgaba and its derivatives for the treatment of pain | 30 Dec, 2018 | Expired |
| US6274171 | Extended release formulation of venlafaxine hydrochloride | 20 Sep, 2017 | Expired |
| US6403120 | Extended release formulation of venlafaxine hydrochloride | 20 Sep, 2017 | Expired |
| US6419958 | Extended release formulation of venlafaxine hydrochloride | 20 Sep, 2017 | Expired |
| US6110940 | Salts of an anti-migraine indole derivative | 29 Aug, 2017 | Expired |
| US6274171 | Extended release formulation of venlafaxine hydrochloride | 20 Mar, 2017 | Expired |
| US6403120 | Extended release formulation of venlafaxine hydrochloride | 20 Mar, 2017 | Expired |
| US6419958 | Extended release formulation of venlafaxine hydrochloride | 20 Mar, 2017 | Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | 08 Jan, 2017 | Expired |
| US5545644 | Indole derivatives | 26 Dec, 2016 | Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | 08 Jul, 2016 | Expired |
| US5760068 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | 02 Dec, 2015 | Expired |
| USRE44048 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | 02 Dec, 2015 | Expired |
| US5760068 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | 02 Jun, 2015 | Expired |
| USRE44048 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | 02 Jun, 2015 | Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same | 11 May, 2015 | Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same | 11 Nov, 2014 | Expired |
| US5466823 | Substituted pyrazolyl benzenesulfonamides | 30 May, 2014 | Expired |
| US5563165 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | 30 May, 2014 | Expired |
| US5916923 | Venlafaxine for the treatment of generalized anxiety disorder | 28 Dec, 2013 | Expired |
| US6444708 | Treatment using venlafaxine | 28 Dec, 2013 | Expired |
| US5466823 | Substituted pyrazolyl benzenesulfonamides | 30 Nov, 2013 | Expired |
| US5563165 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | 30 Nov, 2013 | Expired |
| US5563175 | GABA and L-glutamic acid analogs for antiseizure treatment | 08 Oct, 2013 | Expired |
| US6126971 | Stable oral CI-981 formulation and process for preparing same | 19 Jul, 2013 | Expired |
| US5916923 | Venlafaxine for the treatment of generalized anxiety disorder | 28 Jun, 2013 | Expired |
| US6310101 | Treatments using venlafaxine | 28 Jun, 2013 | Expired |
| US6444708 | Treatment using venlafaxine | 28 Jun, 2013 | Expired |
| US6126971 | Stable oral CI-981 formulation and process for preparing same | 19 Jan, 2013 | Expired |
| US5382600 | 3,3-diphenylpropylamines and pharmaceutical compositions thereof | 25 Sep, 2012 | Expired |
Latest Legal Activities on Upjohn's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Upjohn.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2023 | US9144559 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Jul, 2022 | US8945620 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Jan, 2022 | US10022447 |
|
Email Notification
Critical
| 29 Jul, 2021 | US9144559 |
|
Email Notification
Critical
| 29 Jul, 2021 | US8945620 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 29 Jul, 2021 | US9144559 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 29 Jul, 2021 | US8945620 |
|
Correspondence Address Change
Critical
| 27 Jul, 2021 | US8945620 |
|
Correspondence Address Change
Critical
| 27 Jul, 2021 | US9144559 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jul, 2021 | US10022447 |
|
Email Notification
Critical
| 14 Jul, 2021 | US10022447 |
|
Correspondence Address Change
Critical
| 13 Jul, 2021 | US10022447 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2019 | US9144559 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 17 Jul, 2018 | US10022447 |
|
Recordation of Patent Grant Mailed
Critical
| 17 Jul, 2018 | US10022447 |
Upjohn's Drug Patent Litigations
Upjohn's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 29, 1996, against patent number US6197819. The petitioner , challenged the validity of this patent, with SILVERMAN et al as the respondent. Click below to track the latest information on how companies are challenging Upjohn's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6197819 | October, 1996 |
Decision
(10 Jul, 1997)
| SILVERMAN et al | |
Upjohn Drug Patents' Oppositions Filed in EPO
Upjohn drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 21, 2014, by Strawman Limited. This opposition was filed on patent number EP06809154A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP06809154A | Oct, 2014 | STRAWMAN LIMITED | Opposition rejected |
Upjohn's Family Patents
Upjohn Drug List
Given below is the complete list of Upjohn's drugs and the patents protecting them.
1. Celebrex
Celebrex is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5760068
(Pediatric)
| Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
02 Dec, 2015
(9 years ago)
| Expired |
| USRE44048
(Pediatric)
| 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
02 Dec, 2015
(9 years ago)
| Expired |
| US5760068 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
02 Jun, 2015
(9 years ago)
| Expired |
| USRE44048 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder |
02 Jun, 2015
(9 years ago)
| Expired |
| US5466823
(Pediatric)
| Substituted pyrazolyl benzenesulfonamides |
30 May, 2014
(10 years ago)
| Expired |
| US5563165
(Pediatric)
| Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
30 May, 2014
(10 years ago)
| Expired |
| US5466823 | Substituted pyrazolyl benzenesulfonamides |
30 Nov, 2013
(11 years ago)
| Expired |
| US5563165 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
30 Nov, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Celebrex's drug page
2. Detrol
Detrol is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5382600
(Pediatric)
| 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
25 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Detrol's drug page
3. Detrol La
Detrol La is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6630162
(Pediatric)
| Pharmaceutical formulation and its use |
11 May, 2020
(4 years ago)
| Expired |
| US6911217
(Pediatric)
| Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
11 May, 2020
(4 years ago)
| Expired |
| US6770295
(Pediatric)
| Therapeutic formulation for administering tolterodine with controlled release |
26 Feb, 2020
(5 years ago)
| Expired |
| US6630162 | Pharmaceutical formulation and its use |
11 Nov, 2019
(5 years ago)
| Expired |
| US6911217 | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
11 Nov, 2019
(5 years ago)
| Expired |
| US6770295 | Therapeutic formulation for administering tolterodine with controlled release |
26 Aug, 2019
(5 years ago)
| Expired |
| US5382600
(Pediatric)
| 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
25 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Detrol La's drug page
4. Effexor Xr
Effexor Xr is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6274171
(Pediatric)
| Extended release formulation of venlafaxine hydrochloride |
20 Sep, 2017
(7 years ago)
| Expired |
| US6403120
(Pediatric)
| Extended release formulation of venlafaxine hydrochloride |
20 Sep, 2017
(7 years ago)
| Expired |
| US6419958
(Pediatric)
| Extended release formulation of venlafaxine hydrochloride |
20 Sep, 2017
(7 years ago)
| Expired |
| US6274171 | Extended release formulation of venlafaxine hydrochloride |
20 Mar, 2017
(8 years ago)
| Expired |
| US6403120 | Extended release formulation of venlafaxine hydrochloride |
20 Mar, 2017
(8 years ago)
| Expired |
| US6419958 | Extended release formulation of venlafaxine hydrochloride |
20 Mar, 2017
(8 years ago)
| Expired |
| US5916923
(Pediatric)
| Venlafaxine for the treatment of generalized anxiety disorder |
28 Dec, 2013
(11 years ago)
| Expired |
| US6444708
(Pediatric)
| Treatment using venlafaxine |
28 Dec, 2013
(11 years ago)
| Expired |
| US5916923 | Venlafaxine for the treatment of generalized anxiety disorder |
28 Jun, 2013
(11 years ago)
| Expired |
| US6310101 | Treatments using venlafaxine |
28 Jun, 2013
(11 years ago)
| Expired |
| US6444708 | Treatment using venlafaxine |
28 Jun, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Effexor Xr's drug page
5. Inspra
Inspra is protected by 16 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6863902
(Pediatric)
| Immediate release eplerenone compositions |
10 Oct, 2020
(4 years ago)
| Expired |
| US6410054
(Pediatric)
| Immediate release eplerenone compositions |
08 Jun, 2020
(4 years ago)
| Expired |
| US6495165
(Pediatric)
| Eplerenone compositions having improved bioavailability |
08 Jun, 2020
(4 years ago)
| Expired |
| US6534093
(Pediatric)
| Immediate release eplerenone compositions |
08 Jun, 2020
(4 years ago)
| Expired |
| US6558707
(Pediatric)
| Immediate release eplerenone compositions |
08 Jun, 2020
(4 years ago)
| Expired |
| US7157101
(Pediatric)
| Micronized eplerenone compositions |
08 Jun, 2020
(4 years ago)
| Expired |
| US6410524
(Pediatric)
| Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
05 May, 2020
(5 years ago)
| Expired |
| US6747020
(Pediatric)
| Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
05 May, 2020
(5 years ago)
| Expired |
| US6863902 | Immediate release eplerenone compositions |
10 Apr, 2020
(5 years ago)
| Expired |
| US6410054 | Immediate release eplerenone compositions |
08 Dec, 2019
(5 years ago)
| Expired |
| US6495165 | Eplerenone compositions having improved bioavailability |
08 Dec, 2019
(5 years ago)
| Expired |
| US6534093 | Immediate release eplerenone compositions |
08 Dec, 2019
(5 years ago)
| Expired |
| US6558707 | Immediate release eplerenone compositions |
08 Dec, 2019
(5 years ago)
| Expired |
| US7157101 | Micronized eplerenone compositions |
08 Dec, 2019
(5 years ago)
| Expired |
| US6410524 | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
05 Nov, 2019
(5 years ago)
| Expired |
| US6747020 | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
05 Nov, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inspra's drug page
Explore Our Curated Drug Screens
6. Lipitor
Lipitor is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5969156
(Pediatric)
| Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
08 Jan, 2017
(8 years ago)
| Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
08 Jul, 2016
(8 years ago)
| Expired |
| US5686104
(Pediatric)
| Stable oral CI-981 formulation and process of preparing same |
11 May, 2015
(10 years ago)
| Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same |
11 Nov, 2014
(10 years ago)
| Expired |
| US6126971
(Pediatric)
| Stable oral CI-981 formulation and process for preparing same |
19 Jul, 2013
(11 years ago)
| Expired |
| US6126971 | Stable oral CI-981 formulation and process for preparing same |
19 Jan, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lipitor's drug page
7. Lyrica
Lyrica is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6001876
(Pediatric)
| Isobutylgaba and its derivatives for the treatment of pain |
30 Jun, 2019
(5 years ago)
| Expired |
| US6197819
(Pediatric)
| Gamma amino butyric acid analogs and optical isomers |
30 Jun, 2019
(5 years ago)
| Expired |
| USRE41920
(Pediatric)
| Isobutylgaba and its derivatives for the treatment of pain |
30 Jun, 2019
(5 years ago)
| Expired |
| US6001876 | Isobutylgaba and its derivatives for the treatment of pain |
30 Dec, 2018
(6 years ago)
| Expired |
| US6197819 | Gamma amino butyric acid analogs and optical isomers |
30 Dec, 2018
(6 years ago)
| Expired |
| USRE41920 | Isobutylgaba and its derivatives for the treatment of pain |
30 Dec, 2018
(6 years ago)
| Expired |
| US5563175 | GABA and L-glutamic acid analogs for antiseizure treatment |
08 Oct, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lyrica's drug page
8. Lyrica Cr
Lyrica Cr is protected by 10 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10022447
(Pediatric)
| Solid pharmaceutical compositions containing pregabalin |
02 May, 2027
(1 year, 11 months from now)
| Active |
| US8945620
(Pediatric)
| Solid pharmaceutical compositions containing pregabalin |
02 May, 2027
(1 year, 11 months from now)
| Active |
| US9144559
(Pediatric)
| Solid pharmaceutical compositions containing pregabalin |
02 May, 2027
(1 year, 11 months from now)
| Active |
| US10022447 | Solid pharmaceutical compositions containing pregabalin |
02 Nov, 2026
(1 year, 5 months from now)
| Active |
| US8945620 | Solid pharmaceutical compositions containing pregabalin |
02 Nov, 2026
(1 year, 5 months from now)
| Active |
| US9144559 | Solid pharmaceutical compositions containing pregabalin |
02 Nov, 2026
(1 year, 5 months from now)
| Active |
| US6197819
(Pediatric)
| Gamma amino butyric acid analogs and optical isomers |
30 Jun, 2019
(5 years ago)
| Expired |
| USRE41920
(Pediatric)
| Isobutylgaba and its derivatives for the treatment of pain |
30 Jun, 2019
(5 years ago)
| Expired |
| US6197819 | Gamma amino butyric acid analogs and optical isomers |
30 Dec, 2018
(6 years ago)
| Expired |
| USRE41920 | Isobutylgaba and its derivatives for the treatment of pain |
30 Dec, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lyrica Cr's drug page
9. Relpax
Relpax is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6110940 | Salts of an anti-migraine indole derivative |
29 Aug, 2017
(7 years ago)
| Expired |
| US5545644 | Indole derivatives |
26 Dec, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Relpax's drug page